NanoRepro AG (XTER:NN6) EBIT: €-2.10 Mil (TTM As of Jun. 2025)


XTER:NN6 NanoRepro AG XTER:NN6
63 GF Score
Price €2.08
GF Value €1.01
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is NanoRepro AG EBIT?

NanoRepro AG XTER:NN6 63 EBIT is €-2.10 Mil as of Jun. 2025. GuruFocus rates XTER:NN6 with a GF Score™ of 63/100 and a GF Value™ of €1.01 (Significantly Overvalued). The stock has 6 warning signs investors should review.

NanoRepro AG's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2025 was €-0.90 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2025 was €-2.10 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NanoRepro AG's annualized ROC % for the quarter that ended in Jun. 2025 was -5.96%. NanoRepro AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -42.69%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. NanoRepro AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -11.06%.


NanoRepro AG  (XTER:NN6) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NanoRepro AG's annualized ROC % for the quarter that ended in Jun. 2025 is calculated as:

ROC % (Q: Jun. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Jun. 2025 ))/ count )
=-1.792 * ( 1 - 0% )/( (29.634 + 30.485)/ 2 )
=-1.792/30.0595
=-5.96 %

where

Note: The Operating Income data used here is two times the semi-annual (Jun. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

NanoRepro AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Jun. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.792/( ( (0.347 + max(5.278, 0)) + (0.349 + max(2.422, 0)) )/ 2 )
=-1.792/( ( 5.625 + 2.771 )/ 2 )
=-1.792/4.198
=-42.69 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.265 + 0.901 + 4.411) - (0.293 + 0 + 0.006)
=5.278

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.428 + 0.466 + 1.842) - (0.217 + 0 + 0.097)
=2.422

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

NanoRepro AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2025 )
=-2.095/18.946
=-11.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NanoRepro AG EBIT Related Terms


NanoRepro AG EBIT Historical Data

* Premium members only.

The historical data trend for NanoRepro AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NanoRepro AG EBIT Chart

NanoRepro AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.80 38.81 -4.36 -4.44 -3.45

NanoRepro AG Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.22 -2.23 -2.25 -1.20 -0.90

XTER:NN6 vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, NanoRepro AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NanoRepro AG EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NanoRepro AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NanoRepro AG's EV-to-EBIT falls into.


XTER:NN6
63GF Score
NanoRepro AG XTER:NN6
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NanoRepro AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-2.10 Mil mean?
NanoRepro AG (XTER:NN6) has a EBIT of €-2.10 Mil as of Jun. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NanoRepro AG.
Is NanoRepro AG's EBIT too high?
NanoRepro AG's current EBIT is €-2.10 Mil. Overall, NanoRepro AG has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's EBIT compare to TMO and DHR?
NanoRepro AG's EBIT of €-2.10 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NanoRepro AG. NanoRepro AG's current EBIT is €-2.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (XTER:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.01, compared to a current price of €2.08 — trading 105.9% above its estimated fair value. The current EBIT is €-2.10 Mil. NanoRepro AG's overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For NanoRepro AG (XTER:NN6), the current EBIT is €-2.10 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NanoRepro AG (XTER:NN6) Overvalued in 2026?

Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued. The current stock price of €2.08 is trading 105.9% above its estimated GF Value™ of €1.01. GuruFocus considers NanoRepro AG to be Significantly Overvalued.

Key valuation signals for XTER:NN6:

  • EBIT: €-2.10 Mil
  • GF Value™: €1.01 vs. price of €2.08 (105.9% above fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the XTER:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NanoRepro AG Business Description

Address Untergasse 8, Marburg, DEU, 35037
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
63GF Score

Get the complete analysis for XTER:NN6

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.08
Price
€1.01
GF Value